Table III.

Improvement in lung function in the budesonide arm, at each visit

	Month of follow-up
	0	2	4	12	16	24	28	36	40	48
FEV1 (%pred)
Non-overweight	ns	5.4*	5.3*	5.8	5.1	3.3*	2.5*	3.7	2.5*	3.3*
Overweight	ns	3.6	3.9	3.7	3.5	ns	ns	ns	ns	ns
FEV1/FVC (%)
Non-overweight	ns	2.9*	2.8*	3.5*	3.1*	2.5*	2.1*	2.8*	2.1*	2.1*
Overweight	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns
BDR (%FEV1)
Non-overweight	ns	−2.3	−2.4	−3.8*	−3.5*	−2.4*	−1.5*	−2.3*	−1.8*	−1.9*
Overweight	ns	−2.4	−2.9	−2.9	−3.1	ns	ns	ns	ns	ns

Predicted improvement in lung function with budesonide (compared to placebo/nedocromil) at each individual visit, based on means from multivariate mixed effects regression models. ns: No statistically significant improvement with budesonide at that time point.

^*p<0.05 for comparison between the improvement in the overweight vs the non-overweight group (t-test for the difference of the means from the longitudinal models, assuming all other covariates equal).